Patient Community

How Alex Trebek raised awareness about pancreatic cancer | Becker’s Hospital Review | 11/10/2020

mber is Pancreatic Cancer Awareness Month, and amid the news of Jeopardy! host Alex Trebek’s death, the lasting legacy he left on pancreatic cancer awareness and the patient community lives on. After Mr. Trebek shared the news of his stage 4 pancreatic cancer diagnosis in March 2019, he candidly spoke about the physical and emotional side effects that came along with the disease and its treatment, an effort that ultimately …

Three Questions that Determine if Your Brand Is Patient Ready – PM360 | 11/9/2020

… patient ready brand is one that engages with patients in a meaningful way, with communications that are real and authentic to their experience. Patient ready brands put in the hard work to understand their patient community ‚Äôs needs and identify how‚Äîand if‚Äîthose needs are being addressed elsewhere. They also assess their own internal processes and resources to identify and fill any gaps. As a result, they create the …

Follow Patient Community:    

Adamas Reports Third Quarter 2020 Financial Results | 11/5/2020

… quarter ended September 30, 2020, and recent corporate highlights. ‚ÄúAdamas continues to embrace operational excellence and delivered a strong performance in a complex environment. Our employees remain steadfast in their mission to serve the patient community which is particularly vulnerable during the pandemic,‚Äù said Neil F. McFarlane, Chief Executive Officer. ‚ÄúWe have bolstered the Company‚Äôs leadership to accelerate growth and I remain confident in the long-term outlook …

New U. Cancer Center aims to expand research, serve broad patient community | 10/19/2020

New U. Cancer Center aims to expand research, serve broad patient community New center includes research programs surrounding cancer biology, therapeutics, population sciences Sunday, October 18, 2020 Herald File Photo The new Cancer Center, a collaboration between the University and Lifespan, promotes the development of new cancer treatments through ongoing research. The creation of the Cancer Center at Brown University was announced last month and is aimed at promoting research …

Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA | Financial Buzz | 10/15/2020

… the clinical trial. Lysogene is profoundly saddened by the passing of this child and extends its deepest sympathies to the family. The company remains committed to the LYS-SAF302 development program and the Sanfilippo patient community . The company plans to provide further information on the LYS-SAF302 program based on both ongoing data collection and future regulatory status updates. About Lysogene Lysogene is a gene therapy company focused on the …

U.S. FDA Approves Pfizer’s XELJANZ (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | 9/29/2020

… safety information below. “Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community ,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces its utility in the treatment of immune-mediated inflammatory conditions and …

U.S. FDA Approves Pfizers XELJANZ (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | Financial Buzz | 9/29/2020

… safety information below. “Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community ,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces its utility in the treatment of immune-mediated inflammatory conditions and …

U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | Business Wire | 9/28/2020

… safety information below. “Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community ,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces its utility in the treatment of immune-mediated inflammatory conditions and …

** | 9/28/2020**

… safety information below. “Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community ,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces its utility in the treatment of immune-mediated inflammatory conditions and …

U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | BioSpace | 9/28/2020

… safety information below. “Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community ,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces its utility in the treatment of immune-mediated inflammatory conditions and …

Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day | Business Wire | 9/17/2020

… doses of antibody against the chikungunya virus (mRNA-1944) administered via intravenous infusion in healthy adults New next generation MMA candidate (mRNA-3705) protocol revision to enhance operational performance and improve outreach to the patient community New protocol amendment for Phase 1/2 study of propionic acidemia (PA) candidate (mRNA-3927) Moderna currently has 23 mRNA development candidates in its portfolio with 14 in clinical studies. Across Moderna’s pipeline, more than …

Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day - GuruFocus.com | 9/17/2020

… doses of antibody against the chikungunya virus (mRNA-1944) administered via intravenous infusion in healthy adults New next generation MMA candidate (mRNA-3705) protocol revision to enhance operational performance and improve outreach to the patient community New protocol amendment for Phase 1/2 study of propionic acidemia (PA) candidate (mRNA-3927) Moderna currently has 23 mRNA development candidates in its portfolio with 14 in clinical studies. Across Moderna’s pipeline, more than …

Rare Cancer Day 2020 to Take Place on September 30 | PR Newswire | 9/16/2020

… need them most. NORD is made strong together with more than 325 disease-specific member organizations and their communities and collaborates with many other organizations on specific causes of importance to the rare disease patient community . Visit rarediseases.org . SOURCE National Organization for Rare Disorders (NORD) Related Links http://www.rarediseases.org …

Health Goal Attainment of Patients With Chronic Diseases in Web-Based Patient Communities: Content and Survival Analysis | 9/11/2020

… attainment. In this study, we empirically investigate the impact of social support and self-reflection on goal attainment by conducting a survival analysis on a unique data set collected from a leading web-based patient community . Hypotheses Disease Self-Management and Web-Based Health Goal Attainment Disease self-management is a patient-centered approach that reduces health care costs while improving the health status [ 8 ]. Such illness management is especially …

FDA Patient Engagement Opportunities | 9/11/2020

… experience with a disease or condition by talking directly with FDA staff. Listening Sessions can either be FDA-requested (where FDA has a specific set of questions to ask) or patient-led (when a patient community wants to share their perspectives with the FDA). Learn more about Patient Listening Sessions Patient Engagement Collaborative (PEC) The Patient Engagement Collaborative (PEC) is an FDA patient group established in collaboration with the Clinical …

2020 NORD Summit to Feature Leading Experts in Public Policy, Patient Advocacy, Rare Disease Research and Regulatory Science | PR Newswire | 9/10/2020

… need them most. NORD is made strong together with more than 325 disease-specific member organizations and their communities and collaborates with many other organizations on specific causes of importance to the rare disease patient community . Visit rarediseases.org . SOURCE National Organization for Rare Disorders (NORD) Related Links http://www.rarediseases.org …

Top U.S. Kidney Patient Group Unveils New Board Officers And Directors | PR Newswire | 9/10/2020

… leadership team. I also wish to thank my outgoing Board colleagues whose dutiful service to the organization over the past several years helped expand our standing and reach. AAKP continues to educate the kidney patient community on the dangers of COVID-19 as we encourage greater representation of kidney patients and underserved communities in vaccine clinical trials and other kidney-related research initiatives.” Mr. Knight, a former Congressional staffer and …

CREAKYJOINTS | 9/9/2020

… THE SPRING/SUMMER 2021 COLLECTION DURING NEW YORK FASHION WEEK Global Audience Invited to Engage At Home to Celebrate Accessible Fashion UPPER NYACK, NY (August 25, 2020) – CreakyJoints® , a Global Healthy Living Foundation digital patient community for people with all forms of arthritis, today announces it will present the Spring/Summer 2021 Tumbler and Tipsy® by Michael Kuluva collection timed to New York Fashion Week. As a designer with rheumatoid …

Health care conferences should embrace patients as collaborators - STAT | 9/8/2020

… Cystic Fibrosis Foundation’s history in recent years of embracing digital events, from patient-only conferences to livestreaming portions of the North American Cystic Fibrosis Conference, we believe there is an opportunity to engage the patient community at unprecedented levels with this year’s all-digital conference. Providing free admission would be a step in the right direction. It would make us feel welcome at our own annual conference. The $125 general …

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020 | Business & Finance | heraldchronicle.com | Business Wire | 9/8/2020

… debt financing from Deutsche Bank AG . About Cycle Pharmaceuticals Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and services to the under-served rare disease patient community . We focus on rare metabolic and neurological genetic conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Mass. (USA). For more information, please visit www.cyclepharma.com and follow us on Twitter , LinkedIn …

Cycle Pharmaceuticals Secures $25 Million Debt Financing | Business & Finance | manchestertimes.com | Business Wire | 9/7/2020

… UK Cambridge Institute, University of Cambridge. About Cycle Pharmaceuticals Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and services to the under-served rare disease patient community . We focus on rare genetic metabolic disorders and neurological conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Mass. (USA). For more information, please visit www.cyclepharma.com and follow us on Twitter …

Growing group of COVID-19 long-haulers warrant more coverage — and sensitivity | 9/4/2020

… of patients referred to as long-haulers . As a journalist, Lowenstein searched for stories that mirrored her experience . She ended up co-founding an online COVID-19 support group to bring together a growing patient community and raise awareness of an often-dismissed group. long-haulers, aspect of life,” she said. Lowenstein, also a consultant and speaker based in New York City, joined researcher and cardiologist Dr. Haider Warraich and …

** | 9/3/2020**

CreakyJoints® , a Global Healthy Living Foundation digital patient community for people with all forms of arthritis, today announces it will present the Spring/Summer 2021 Tumbler and Tipsy® by Michael Kuluva collection timed to New York Fashion Week. As a designer with rheumatoid arthritis (RA) and CreakyJoints member, Michael advocates for social distancing and following local guidelines to stay safe and reduce the spread of the COVID-19 virus. Therefore …

CreakyJoints Presents Tumbler and Tipsy by Michael Kuluva Virtual Presentation of the Spring/Summer 2021 Collection During New York Fashion Week | Business Wire | 9/3/2020

UPPER NYACK, N.Y.- CreakyJoints® , a Global Healthy Living Foundation digital patient community for people with all forms of arthritis, today announces it will present the Spring/Summer 2021 Tumbler and Tipsy® by Michael Kuluva collection timed to New York Fashion Week. As a designer with rheumatoid arthritis (RA) and CreakyJoints member, Michael advocates for social distancing and following local guidelines to stay safe and reduce the spread of the COVID …

Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders | PR Newswire | 9/1/2020

… at The Tempest Finalists will pitch their business solutions during the two-day virtual summit on October 14-15, 2020 to an expert panel of judges who represent various facets of the healthcare industry and patient community to assess each solution through a unique lens. The judging panel will include: David Hunt , Chief Digital Officer at Havas Health & You Geri-Lynn Utter , PsyD, Medical Science Liaison at Orexo Pharmaceuticals Kajsa Gatenbeck …

Patient Engagement

Three Questions that Determine if Your Brand Is Patient Ready – PM360 | 11/9/2020

Today, most brand marketers recognize the importance of having a solid patient engagement plan. Building that plan, though, is incredibly challenging. You must consider and assess a lot, from balancing financial resources and ensuring patient … ready brands put in the hard work to understand their patient community‚Äôs needs and identify how‚Äîand if‚Äîthose needs are being addressed elsewhere. They also assess their own internal processes and resources to …

Clinical Research

New U. Cancer Center aims to expand research, serve broad patient community | 10/19/2020

New U. Cancer Center aims to expand research, serve broad patient community New center includes research programs surrounding cancer biology, therapeutics, population sciences Sunday, October 18, 2020 Herald File Photo The new Cancer Center, a … Care New England to unify the clinical infrastructure, expertise in clinical research and cancer care as well as other resources relevant to cancer prevention and treatment present in Rhode Island” said Benedito Carneiro, the director …

Gene Therapy

Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA | Financial Buzz | 10/15/2020

Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS) , a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that a patient has passed away in the AAVance clinical trial (NCT03612869), a … committed to the LYS-SAF302 development program and the Sanfilippo patient community. The company plans to provide further information on the LYS-SAF302 program based on both ongoing data collection and future regulatory status updates …

Food and Drug Administration

U.S. FDA Approves Pfizer’s XELJANZ (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | 9/29/2020

Print NEW YORK–( BUSINESS WIRE )– Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ ® (tofacitinib) for the treatment of children and adolescents 2 years and older … so we are proud to now offer XELJANZ to this patient community,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces …

Clinical Data

U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | Business Wire | 9/28/2020

… or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development … launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities …

NIH

Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day | Business Wire | 9/17/2020

… Infectious Diseases COVID vaccine candidate (mRNA-1273) Phase 3 COVE study of 30,000 volunteers in the U.S. being conducted with NIH and BARDA has enrolled 25,296 participants as of September 16, 2020; 10,025 participants have … revision to enhance operational performance and improve outreach to the patient community New protocol amendment for Phase 1/2 study of propionic acidemia (PA) candidate (mRNA-3927) Moderna currently has 23 mRNA development candidates in its …

Department of Health and Human Services

2020 NORD Summit to Feature Leading Experts in Public Policy, Patient Advocacy, Rare Disease Research and Regulatory Science | PR Newswire | 9/10/2020

… advocates, thought leaders and subject matter experts. Sessions include: Congresswoman Robin Kelly (IL-02) together with representatives from the US Department of Health and Human Services, the New Hampshire State Legislature, the University of Minnesota … organizations on specific causes of importance to the rare disease patient community. Visit rarediseases.org . SOURCE National Organization for Rare Disorders (NORD) Related Links http://www.rarediseases.org …

COVID-19

CreakyJoints Presents Tumbler and Tipsy by Michael Kuluva Virtual Presentation of the Spring/Summer 2021 Collection During New York Fashion Week | Business Wire | 9/3/2020

UPPER NYACK, N.Y.- CreakyJoints® , a Global Healthy Living Foundation digital patient community for people with all forms of arthritis, today announces it will present the Spring/Summer 2021 Tumbler and Tipsy® by Michael Kuluva collection timed to New York Fashion Week. As a designer with rheumatoid arthritis (RA) and CreakyJoints member, Michael advocates for social distancing and following local guidelines to stay safe and reduce the spread of the COVID …

Digital Health

Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders | PR Newswire | 9/1/2020

… with unique solutions that address unmet needs afflicting patients and support partners in the recovery journey: Marisa Barbieri , CEO and Digital Health Solutions Architect at Competitive Solutions Rohan Dixit , Founder and CEO at Lief Therapeutics … judges who represent various facets of the healthcare industry and patient community to assess each solution through a unique lens. The judging panel will include: David Hunt , Chief Digital Officer at Havas Health & You Geri …

National Institutes of Health

Global Summit On Kidney Disease Innovation And Choice Engages 70 Countries | PR Newswire | 7/22/2020

… of Diabetes and Digestive and Kidney Diseases (NIDDK) and Chief of the Molecular and Clinical Hematology Branch at the U.S. National Institutes of Health (NIH). Dr. Rodgers is an international voice for patient inclusion in … announcement is the first of its kind in the kidney patient community and signals widening support for an International Kidney Consortium . All 2020 Global Summit presentations are now available OnDemand and will continue to reach …

Patient-Centered Research

Global Healthy Living Foundation Launches Autoimmune Patient COVID-19 Research Project | Business Wire | 4/22/2020

UPPER NYACK, N.Y.–(BUSINESS WIRE)–Apr 22, 2020– Today the Global Healthy Living Foundation (GHLF) and CreakyJoints ®, its digital patient community for people with all forms of arthritis, announced the launch of the Autoimmune COVID … 19,” said study lead Shilpa Venkatachalam, PhD., Associate Director of Patient-Centered Research at CreakyJoints and co-principal investigator of ArthritisPower. “We need information about the impact of COVID-19 on patients with autoimmune, rheumatic …

Biotech

The PTEN Hamartoma Tumor Syndrome (PHTS) Foundation announces receipt of the Russel Hill Cancer Foundation Grant Award | PRWeb | 4/21/2020

… a $15,000 grant award from the Russel Hill Cancer Foundation. The award will support a collaborative project with HudsonAlpha Associate Biotech iXpressGenes, Inc. aimed at accelerating PHTS Research. “Currently, there is no cure for our … 501C3 organization founded in December 2013 to support the PHTS patient community through programs and patient assistance, research initiatives, and education. The Russell Hill Cancer Foundation of Huntsville, Alabama is a 501C3 organization committed to …

Medicare

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis | Globe Newswire | 4/20/2020

patient community and will continue to do what we can to ensure our patients and healthcare professionals are supported during these challenging times.” The VALCHLOR copay program is only available for US and Puerto Rico residents who are 18 or older and have commercial health insurance. Patients ineligible for the VALCHLOR copay/coinsurance program include those enrolled in Medicare, Medicaid, VA/DoD (Tricare), the Indian Health Service, or any other …

CDC

Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update | Globe Newswire | 4/2/2020

… its operations. The Company has taken steps in line with guidance from the U.S. Centers for Disease Control and Prevention (CDC) and the State of California to protect the health and safety of its employees … working closely with its clinical sites, physician partners and the patient community to monitor the potential impact of the evolving COVID-19 pandemic. The Company remains committed to its clinical programs and development plans, but …

Medical Education

PlatformQ Health & GBS|CIDP Foundation International Release Next Video Education Program | PRWeb | 12/4/2019

… to treatment, particularly with IVIG, so the next program focuses on those themes,” explained Dr. Anne Roc, Vice President of Medical Education at PlatformQ Health. “With so much ground to cover on this rare neurologic … research funding and advocacy for legislation that directly affects our patient community. We are working toward a future where patients coping with this rare set of neurologic conditions do not suffer alone and that every …

Mental Health

Podcast | Chronic Illness and Depression | 12/2/2019

… Zimmerman also started to experience depression. Unable to tackle both, Jackie chose to focus on her physical health, letting her mental health deteriorate quickly — and dangerously. In this episode, we discuss the mind-body connection … as an authority on chronic illness, patient-centric healthcare, and patient community building. She lives with multiple sclerosis, ulcerative colitis, and depression. You can find her online at JackieZimmerman.co , Twitter , Facebook , and LinkedIn. Computer Generated …

Regenerative Medicine

Remarks by Anna Abram to the Biocom Celebration of Life Dinner - 11/21/2019 | 11/22/2019

… to medical product development for rare diseases; and most recently, we created the Patient Engagement Collaborative, a forum for the patient community and regulators to discuss increasing patient engagement in medical product development and regulatory … created a priority review pathway for breakthrough medical devices, the regenerative medicine advanced therapy designation program, and a limited population approval pathway for antibacterial and antifungal drugs, among other things. It also established a clear …

Patient Recruitment

StudyKIK Introduces its New Clinical Trial Patient Recruitment Call Center Technology Platform, Increasing its Pre-screen Volume to Over 4,000 Patients Daily | PRWeb | 11/21/2019

StudyKIK Introduces its New Clinical Trial Patient Recruitment Call Center Technology Platform, Increasing its Pre-screen Volume to Over 4,000 Patients Daily Share Article The newest custom technology update to StudyKIK’s in-house Patient Qualification Department will allow StudyKIK to provide wider pre-screening support to research site partners, increasing clinical trial feasibility. These improvements have increased our agents’ efficiency by 90% and improved the quality of our pre-screening …

Precision Medicine

Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress | PR Newswire | 11/20/2019

SOUTH SAN FRANCISCO, Calif. , Nov. 20, IDEAYA Biosciences, Inc. (Nasdaq: IDYA ), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced it has presented data from … continued collaboration with our clinical investigators, the FDA and the patient community,” said Yujiro S. Hata , Chief Executive Officer and President at IDEAYA Biosciences. About IDEAYA Biosciences IDEAYA is an oncology-focused precision medicine company …

Hospital Management

WiSilica and CMS Team-up to provide RTLS solutions to Counties Manukau District Health Board, NZ | Markets Insider | Business Insider | 11/14/2019

hospital management in stopping child abductions and child-swaps, besides tracking and securing hospital assets. It brings more awareness and alertness among the staff and the healthcare professionals through real-time alerts to quickly respond to child theft and other breaches. The initiative is to scale and leverage County Manukau District Health Board’s commitment to ensuring security and on-time services to its patient community. Addressing to the needs, WiSilica …

RTLS

WiSilica and CMS Team-up to provide RTLS solutions to Counties Manukau District Health Board, NZ | Markets Insider | Business Insider | 11/14/2019

… time alerts to quickly respond to child theft and other breaches. The initiative is to scale and leverage County Manukau District Health Board’s commitment to ensuring security and on-time services to its patient community. Addressing to the needs, WiSilica, in collaboration with CMS, deployed wearable tags and asset tags that track infants and hospital devices in real-time. Being a comprehensive tracking and alerting system, the tags send instant …

Patient Safety

Henry Ford Health System Recognized as Center of Excellence by Sunquest Information Systems | 11/13/2019

patient community and drive greater efficiency for the organization. The Center of Excellence program recognizes world-class health systems that utilize Sunquest solutions to support the strategic direction of their organization. This includes establishing and promoting best practices that improve patient safety, decrease the cost of healthcare, streamline provider care, and provide thought leadership and recommendations on new and existing Sunquest products. The Sunquest Center of Excellence program identifies those …

EMR

Medical Marijuana to Methotrexate: Arthritis Patients Make Multidimensional Treatment Choices, Studies Show | Business Wire | 11/9/2019

UPPER NYACK, N.Y.- CreakyJoints® , a Global Healthy Living Foundation patient community, will present five posters, some in partnership with major academic institutions, at the 2019 ACR/ARP Annual Meeting in Atlanta, GA (Nov. 8-12, 2019 … 435) Comparison of Medication New User Definitions in Multi-Specialty EMR Data (Abstract: 2067) Art for Arthritis: A New Approach (Abstract: PP06) About ArthritisPower® Created by CreakyJoints ® and supported by a multiyear, multimillion dollar investment …

Electronic Medical Record

Association between potentially inappropriate medications at discharge and unplanned readmissions among hospitalised elderly patients at a single centre in Japan: a prospective observational study | BMJ | 11/7/2019

… study design limited the generalisability of the results. The data on readmission might be inaccurate due to the use of electronic medical records to acquire the data. Introduction Inappropriate prescribing, which encompasses potentially inappropriate medications … results of this research to study participants or the relevant patient community. Results The baseline characteristics of the 739 elderly hospitalised patients are shown in table 1 . Of those, the median patient age was 82 …

Medical Research

2019 NORD Summit Breaks Records with Largest Attendance Ever! | PR Newswire | 10/23/2019

medical research and providing patient and family services for those who need them most. NORD is made strong together with over 275 disease-specific member organizations and their communities and collaborates with many other organizations on specific causes of importance to the rare disease patient community. Visit rarediseases.org . SOURCE National Organization for Rare Disorders (NORD) Related Links http://www.rarediseases.org …

Pfizer

U.S. FDA Approves Pfizer’s XELJANZ (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | 9/29/2020

Print NEW YORK–( BUSINESS WIRE )– Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ ® (tofacitinib) for the treatment of children and adolescents 2 years and older … so we are proud to now offer XELJANZ to this patient community,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces …

PlatformQ Health

NORD taps PlatformQ Health to Transition Living Rare, Living Stronger Patient and Family Forum to Comprehensive, Interactive Virtual Event | PRWeb | 7/13/2020

NORD taps PlatformQ Health to Transition Living Rare, Living Stronger Patient and Family Forum to Comprehensive, Interactive Virtual Event Share Article Rare disease conference to be held online, featuring dedicated tracks patients and families and … organizations on specific causes of importance to the rare disease patient community. Visit rarediseases.org About PlatformQ Health PlatformQ Health Education is the leading provider of interactive digital medical education for clinicians, patients and caregivers. To …

AbbVie

IMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström’s Macroglobulinemia (WM) | PR Newswire | 6/23/2020

… the U.S. News provided by Jun 23, 2020, 07:30 ET Share this article NORTH CHICAGO, Ill. , June 23, 2020 /PRNewswire/ – AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food … option for WM patients and our commitment to supporting this patient community.” WM typically affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may also be affected …

WEGO Health

WEGO Health Launches Pharmaceutical Grade Influencer Marketing℠ | PRWeb | 6/17/2020

WEGO Health Launches Pharmaceutical Grade Influencer Marketing℠ Share Article Trust versus results. Why should brands have to choose? BOSTON WEGO Health, a mission-driven patient collaboration company, launched today the only influencer marketing program designed … create content crafted to meet the authentic needs of the patient community as well as pharma business and regulatory requirements,” says WEGO Health Chief Client Officer, Kristen Hartman. “But the real excitement is in how …

Johnson & Johnson

4 Ways to Help Nurses During the Coronavirus Pandemic | PR Newswire | 4/20/2020

… Support Fund The American Nurses Foundation’s Coronavirus Response Fund for Nurses is a nationwide effort to provide direct financial assistance, mental health support and science- and data-based resources to benefit nurses. The Johnson & Johnson company and its TYLENOL brand made a $1.5 million commitment to launch this fund. A portion of the donations will help support Nurses House, Inc. , a national fund for registered nurses in need. The American …

Protalix

Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement | PR Newswire | 3/18/2020

CARMIEL, Israel , March 18, Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein … Protalix’s commitment to bring important treatment options to the Fabry patient community,” said Dror Bashan , Protalix’s President and Chief Executive Officer. “This funding gives us the runway and ability to complete our pivotal Phase III …

Sanofi Genzyme

Area Business Manager Dupixent - Tampa - Tampa, FL, , USA #jobs #Tampa pls RT | 11/27/2019

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Sanofi Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research, collaboration with the global patient community, and with the compassion and commitment of our …

Genzyme

Area Business Manager Dupixent - Tampa - Tampa, FL, , USA #jobs #Tampa pls RT | 11/27/2019

Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Sanofi Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research, collaboration with the global patient community, and with the compassion and commitment of our employees …

Genentech

Associate Director - Alliance and Advocacy Relations : South San Francisco | 11/26/2019

Genentech representative to external advocates, establish and maintain in-depth knowledge of Genentech business plans, and engage relevant advocates to best support the patient community and Genentech’s priorities. This individual will be a member of Genentech’s BioOncology AAR team and will report to the Director for BioOncology-AAR. This position location is flexible and can be based either in Genentech’s South San Francisco headquarters or the Washington D.C. office. Sample …

Amgen

Medical Marijuana to Methotrexate: Arthritis Patients Make Multidimensional Treatment Choices, Studies Show | Business Wire | 11/9/2019

UPPER NYACK, N.Y.- CreakyJoints® , a Global Healthy Living Foundation patient community, will present five posters, some in partnership with major academic institutions, at the 2019 ACR/ARP Annual Meeting in Atlanta, GA (Nov. 8-12, 2019 … impossible without MTX. This study was conducted with support from Amgen Inc and with GHLF research funds. Which symptoms are most important to arthritis patients in their experience and tracking of disease activity and treatment …

Novartis

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

… prefer that I speak more often more publicly on this issue, and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this … Spinraza sites treating SMA. Based on the very strong results Novartis demonstrated with their recent launches of Zolgensma and understanding the label and the differences in patient population sizes between the two disease states, we …

Sarepta Therapeutics

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants Ian Estepan - Senior Vice President, Chief of Staff and Corporate Affairs Douglas Ingram - President and Chief Executive … issue, and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this therapy a lot faster. I have no intention of doing …

Eli Lilly

Synspira Therapeutics Appoints Industry Leaders Dr. Alexey Margolin And Robert K. Coughlin To Board Of Directors | PR Newswire | 10/28/2019

… record of raising capital and growing companies, as well as a deep understanding of the cystic fibrosis and rare disease patient community we are focused on. We look forward to their contributions.” Dr. Alexey Margolin … and CEO until 2010, when the company was acquired by Eli Lilly. As Chief Scientific Officer for Altus Pharmaceuticals, he helped build a portfolio of products for rare diseases. Dr. Margolin is the author of …

Ultragenyx

GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 | Globe Newswire | 9/3/2019

September 03, 2019 08:30 ET Source: Ultragenyx Pharmaceutical Inc.; GeneTx Biotherapeutics LLC SARASOTA, Fla. and NOVATO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) – GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused … GeneTx, a company launched because of the efforts of this patient community, is the first in this space to receive the Rare Pediatric Disease Designation.” GTX-102 is currently in late preclinical development, and an …

Quintiles

Khiron Secures Exclusive Endorsement from The Colombian Association of Gerontology and Geriatrics | PR Newswire | 8/29/2019

… million patients in Colombia are elderly and suffer from chronic pain, anxiety, depression or are in palliative care (Source: IMS quintiles) Khiron medical product pipeline focused on priority conditions associated with aging, including chronic pain … market as part of our strategy to focus on the patient community in Latin America . This relationship with CAGG increases our ability to deepen interactions with health professionals in the field and to educate on …

Nurx

Nurx Receives $52 Million For Expanding Access To Sensitive Health Needs | 8/26/2019

Nurx, a health tech company that is providing convenient and affordable care for sensitive needs, announced it raised $52 million Nurx — the health tech company providing convenient and affordable care for sensitive health needs — announced … services for sensitive health needs as well as grow its patient community to reach more people who face systemic barriers to healthcare. And Nurx will also focus on expanding its medical provider team as well …

GSK

‘A Vision for Lupus’ Report, Published Ahead of World Lupus Day, Highlights an Important Need to Improve Quality of Care for Lupus Patients | Business Wire | 5/9/2019

… patients and their families living with lupus, a chronic, inflammatory, autoimmune disease that affects approximately five million people globally. 1,2 GSK conceived, developed and led the ‘ A Vision for Lupus ’ initiative in collaboration with a … report will help raise the global voice of the lupus patient community and drive a much-needed change to improve the lives of patients living with lupus.” Notes to editors About Systemic Lupus Erythematosus (SLE …

Merrill Lynch

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

… Whitney Ijem - Guggenheim Christopher Marai - Nomura Brian Abrahams - RBC Capital Markets Debjit Chattopadhyay - H.C. Wainwright Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Salveen Richter - Goldman Sachs Danielle Brill - Piper Jaffray Joel Beatty … issue, and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this therapy a lot faster. I have no intention of doing …

UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases | Business Wire | 10/10/2019

… Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharmaceuticals commented: “UCB shares our commitment to the rare disease patient community and our goal of developing novel, accessible, and cost-effective therapies in the … and underwritten by BNP Paribas Fortis and Bank of America Merrill Lynch. Pro-forma for this acquisition, UCB’s new net debt / rEBITDA ratio would be in the range between 1.5 and 2.0 times with rapid …

SVB Leerink

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

… prefer that I speak more often more publicly on this issue, and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this … year. Operator Our next question comes from Joseph Schwartz of SVB Leerink. Your line is open. Unidentified Analyst Hi, good evening. Thanks for taking my questions. This is Dae Gon [ph] dialing in for Joe …

Sarepta Therapeutics (SRPT) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… that I speak more often and more publicly on this issue and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this … year. Operator Our next question comes from Joseph Schwartz of SVB Leerink. Your line is open. Dae Gon – SVB Leerink – Analyst Hi, good evening. Thanks for taking the question. This is Dae Gon dialing in …

Piper Jaffray

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

… Debjit Chattopadhyay - H.C. Wainwright Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Salveen Richter - Goldman Sachs Danielle Brill - Piper Jaffray Joel Beatty - Citi Ritu Baral - Cowen Brian Skorney - Robert W. Baird Liisa Bayko … issue, and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this therapy a lot faster. I have no intention of doing …

Adamas Pharmaceuticals, Inc. (ADMS) CEO Gregory Went on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/10/2019

… Medical Officer Conference Call Participants Joshua Schimmer - Evercore ISI Marc Goodman - SVB Leerink Timothy Lugo - William Blair & Company David Amsellem - Piper Jaffray Companies Stacy Ku - Cowen and Company Irina Koffler - Mizuho Securities Tian Sun - Needham … I was just curious if the feedback from the physician, patient community has been that this is more helpful, this is easy, it’s working. Is there anything in the marketing messaging or the focus of …

Goldman Sachs

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

… Abrahams - RBC Capital Markets Debjit Chattopadhyay - H.C. Wainwright Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Salveen Richter - Goldman Sachs Danielle Brill - Piper Jaffray Joel Beatty - Citi Ritu Baral - Cowen Brian Skorney - Robert … issue, and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this therapy a lot faster. I have no intention of doing …

Sarepta Therapeutics (SRPT) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… that I speak more often and more publicly on this issue and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this … mark. Operator Our next question comes from Salveen Richter of Goldman Sachs. Your line is open. Salveen Richter – Goldman Sachs – Analyst Good afternoon. Thanks for taking my question. So with regard to the gene therapy …

William Blair

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

… prefer that I speak more often more publicly on this issue, and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this … afterwards. Operator Our next question comes from Tim Lugo of William Blair. Your line is open. Unidentified Analyst Hi, this is John on for Tim. Thanks for the question. I was just wondering if you …

Sarepta Therapeutics (SRPT) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… that I speak more often and more publicly on this issue and/or that I would attempt to engage the patient community or others to assist, for instance, in applying external pressure to bring this … afterwards. Operator Our next question comes from Tim Lugo of William Blair. Your line is open. John Boyle – William Blair – Analyst Hi. This is John on for Tim. Thanks for the question. I was just …

Centerview Partners

UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases | Business Wire | 10/10/2019

… Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharmaceuticals commented: “UCB shares our commitment to the rare disease patient community and our goal of developing novel, accessible, and cost-effective therapies in the … is acting as legal advisor to UCB on this transaction. Centerview Partners is acting as exclusive financial advisor to Ra Pharma on this transaction. Latham & Watkins LLP is acting as legal advisor to Ra Pharma …

UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases | Business & Finance | manchestertimes.com | Business Wire | 10/10/2019

… Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharmaceuticals commented: “UCB shares our commitment to the rare disease patient community and our goal of developing novel, accessible, and cost-effective therapies in the … is acting as legal advisor to UCB on this transaction. Centerview Partners is acting as exclusive financial advisor to Ra Pharma on this transaction. Latham & Watkins LLP is acting as legal advisor to Ra Pharma …

MD Anderson Cancer Center

Novel Cancer Treatments Arise as Scientists Search for Answers | PR Newswire | 8/25/2020

… there is not enough research within the sector to be certain. Hussein Tawbi , M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, mentioned that having an overactive immune system is the main reason … to better understand the sequential use of treatments for this patient community, and we look forward to learning more about the potential role of the combination of cabozantinib and atezolizumab following checkpoint inhibitor therapy in …

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis | PR Newswire | 11/20/2019

… patient community,” said Dr. Srdan Verstovsek, MD, PhD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas . “JAK inhibitors remain the cornerstone of myelofibrosis treatment but new options in this class are needed for the majority of patients who have difficulty tolerating the currently approved agents due to the cytopenias they can exacerbate or induce. Momelotinib could become a suitable alternative for …

Mayo Clinic

Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy | PR Newswire | 7/21/2020

… treatment for this devastating disease,” commented Dr. Phillip A. Low , M.D., Robert D. and Patricia E. Kern Professor of Neurology, Mayo Clinic, Rochester, MN. “I applaud the true champions of the M-STAR trial – the … Executive Director of the Defeat MSA Alliance, commented, “The MSA patient community is optimistic that the M-STAR study will figure prominently in the history of our collective efforts to defeat this debilitating disease. On …

2019 Beyond Celiac Research Summit Forges Ahead for New Treatments and a Cure | Globe Newswire | 11/5/2019

patient community faces in managing celiac disease and the experiences of clinical trial participants. In addition, Joseph A. Murray, MD of Mayo Clinic and leading researcher in the field of celiac disease, will discuss the roadblocks to research: Where we are now and what barriers remain on the path to actual therapies for celiac disease, including clinical trial update. Register online for a link to the webcast. The 2019 Beyond …

The University of Texas MD Anderson Cancer Center

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis – Company Announcement - FT.com | Financial Times | 11/20/2019

… patient community,” said Dr. Srdan Verstovsek , MD, PhD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas . “JAK inhibitors remain the cornerstone of myelofibrosis treatment but new options in this class are needed for the majority of patients who have difficulty tolerating the currently approved agents due to the cytopenias they can exacerbate or induce. Momelotinib could become a suitable alternative for …

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis | PR Newswire | 11/20/2019

… patient community,” said Dr. Srdan Verstovsek, MD, PhD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas . “JAK inhibitors remain the cornerstone of myelofibrosis treatment but new options in this class are needed for the majority of patients who have difficulty tolerating the currently approved agents due to the cytopenias they can exacerbate or induce. Momelotinib could become a suitable alternative for …

Peter L. Saltonstall

2020 NORD Summit to Feature Leading Experts in Public Policy, Patient Advocacy, Rare Disease Research and Regulatory Science | PR Newswire | 9/10/2020

… for the community to come together virtually to share perspectives and address time-sensitive topics,” said NORD President and CEO Peter L. Saltonstall . “At the NORD Summit, we will tackle the issues that matter most … organizations on specific causes of importance to the rare disease patient community. Visit rarediseases.org . SOURCE National Organization for Rare Disorders (NORD) Related Links http://www.rarediseases.org …

NORD Welcomes Vice President of Information Technology Prashant Goel, Who Joins to Lead a Team of IT Innovators in Rare Disease | PR Newswire | 3/24/2020

… GDPR, CCPA, PHI, PCI, and COPPA. “The technical team at NORD has vast experience, both in length and depth,” said Peter L. Saltonstall , President and CEO of NORD. “Under Prashant’s leadership we will light the … organizations on specific causes of importance to the rare disease patient community. Visit rarediseases.org . SOURCE National Organization for Rare Disorders (NORD) Related Links https://rarediseases.org …

Srdan Verstovsek

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis – Company Announcement - FT.com | Financial Times | 11/20/2019

… patient community,” said Dr. Srdan Verstovsek , MD, PhD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas . “JAK inhibitors remain the cornerstone of myelofibrosis treatment but new options in this class are needed for the majority of patients who have difficulty tolerating the currently approved agents due to the cytopenias they can exacerbate or induce. Momelotinib could become a suitable alternative for …

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis | PR Newswire | 11/20/2019

… patient community,” said Dr. Srdan Verstovsek, MD, PhD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas . “JAK inhibitors remain the cornerstone of myelofibrosis treatment but new options in this class are needed for the majority of patients who have difficulty tolerating the currently approved agents due to the cytopenias they can exacerbate or induce. Momelotinib could become a suitable alternative for …

Seth Ginsberg

Medical Marijuana to Methotrexate: Arthritis Patients Make Multidimensional Treatment Choices, Studies Show | Business Wire | 11/9/2019

UPPER NYACK, N.Y.- CreakyJoints® , a Global Healthy Living Foundation patient community, will present five posters, some in partnership with major academic institutions, at the 2019 ACR/ARP Annual Meeting in Atlanta, GA (Nov. 8-12, 2019 … and their related information needs. CreakyJoints independently funded this study. Seth Ginsberg, president and co-founder of CreakyJoints added, “What’s important to emphasize is that while marijuana (and CBD) usage is growing among people with …

Medical Marijuana to Methotrexate: Arthritis Patients Make Multidimensional Treatment Choices, Studies Show | Business & Finance | manchestertimes.com | Business Wire | 11/9/2019

UPPER NYACK, N.Y.–(BUSINESS WIRE)–Nov 9, 2019– CreakyJoints® , a Global Healthy Living Foundation patient community, will present five posters, some in partnership with major academic institutions, at the 2019 ACR/ARP Annual Meeting in … and their related information needs. CreakyJoints independently funded this study. Seth Ginsberg, president and co-founder of CreakyJoints added, “What’s important to emphasize is that while marijuana (and CBD) usage is growing among people with …

Dan Anglin

CannAmerica and Canna Provisions Enter Long-Term Licensing Agreement to Distribute Licensed Products in Massachusetts | PR Newswire | 10/30/2019

… with Canna Provisions Inc. for manufacturing and distribution of CannAmerica branded edibles products in the great State of Massachusetts ,” said Dan Anglin, CEO and Co-Founder of CannAmerica. “Having the opportunity to work in concert … and variety of products available to the Massachusetts medical cannabis patient community, that Canna Provisions, Inc. will manufacture and distribute CannAmerica branded products in Massachusetts , are forward-looking statements and contain forward-looking information. Generally …

CannAmerica and Total Herbal Care Corporation Enter Long-Term Licensing Agreement to Distribute Licensed Products in Oklahoma | Markets Insider | Business Insider | 7/3/2019

… that we expect CannAmerica branded products to be available in the Oklahoma medical cannabis market in the coming months,” said Dan Anglin, CEO and Co-Founder of CannAmerica. “By signing this Agreement, CannAmerica will be … and variety of products available to the Oklahoma medical cannabis patient community.” The Agreement aligns with the Company’s established goals to expand into additional markets in the United States during 2019. “We are very proud …

Paula Martin

Khiron Secures Exclusive Endorsement from The Colombian Association of Gerontology and Geriatrics | Markets Insider | Business Insider | 8/29/2019

… Source: IMS quintiles) Khiron medical product pipeline focused on priority conditions associated with aging, including chronic pain management Khiron neurologist Paula Martinez to present keynote to more than 1,500 health professionals at Association congress in … market as part of our strategy to focus on the patient community in Latin America . This relationship with CAGG increases our ability to deepen interactions with health professionals in the field and to educate on …

Khiron Secures Exclusive Endorsement from The Colombian Association of Gerontology and Geriatrics | Markets Insider | Business Insider | 8/29/2019

… Source: IMS quintiles) Khiron medical product pipeline focused on priority conditions associated with aging, including chronic pain management Khiron neurologist Paula Martinez to present keynote to more than 1,500 health professionals at Association congress in … market as part of our strategy to focus on the patient community in Latin America . This relationship with CAGG increases our ability to deepen interactions with health professionals in the field and to educate on …

Varsha Rao

Nurx Introduces Convenient & Private STI Home Test Kits | PR Newswire | 7/10/2019

Varsha Rao . “We have built a significant amount of trust among our patient community for contraception and HIV prevention, and we’re committed to continue empowering our patients with the resources and knowledge on how to best protect themselves and their partners.” With Nurx’s STI Home Test Kits, there’s no need to find an available appointment, travel to the doctor’s office or clinic, or wait in line at the pharmacy. After …

Nurx Names Dr. Kim Boyd as New Medical Director | PR Newswire | 5/24/2019

… high standards for patient care and clinical protocols are upheld, especially as the digital health organization continues to grow its patient community and introduce new healthcare services. Nurx is the leading online provider for both … providing our patients with high-quality care,” said Nurx CEO Varsha Rao . “Her perspective on how to provide virtual care and how it can best complement traditional care gives us further confidence that we’ll be …

Kathleen O'Donnell

ICYMI: ReWalk’s Restore technology for stroke patients featured in MD | PR Newswire | 11/30/2017

… assistive medical devices, and outlines the inspiration for a soft suit exoskeleton, with interviews with ReWalk CEO Larry Jasinski and Kathleen O’Donnell , lead of the medical exosuit program at Harvard’s Wyss Institute, ReWalk’s collaborative partner … is a soft suit exoskeleton designed for the stroke survivor patient community; exosuits are expected to offer additional use for other patient populations, including individuals with Parkinson’s Disease, Multiple Sclerosis or other mobility challenges where …

ICYMI: ReWalk’s Restore technology for stroke patients featured in MD | PR Newswire | 11/30/2017

… assistive medical devices, and outlines the inspiration for a soft suit exoskeleton, with interviews with ReWalk CEO Larry Jasinski and Kathleen O’Donnell , lead of the medical exosuit program at Harvard’s Wyss Institute, ReWalk’s collaborative partner … is a soft suit exoskeleton designed for the stroke survivor patient community; exosuits are expected to offer additional use for other patient populations, including individuals with Parkinson’s Disease, Multiple Sclerosis or other mobility challenges where …

Brett Haumann

Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease | PR Newswire | 11/13/2017

… patient community. While a significant number of COPD patients require or prefer nebulized therapy, these same patients currently have no access to a nebulized LAMA, broadly considered the cornerstone of COPD maintenance therapy,” said Brett Haumann , MD, Chief Medical Officer at Theravance Biopharma. “We are pleased with the comprehensive data package that was generated through our Phase 3 efficacy and safety studies and look forward to the FDA’s review of …

Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in | PR Newswire | 11/13/2017

… patient community. While a significant number of COPD patients require or prefer nebulized therapy, these same patients currently have no access to a nebulized LAMA, broadly considered the cornerstone of COPD maintenance therapy,” said Brett Haumann , MD, Chief Medical Officer at Theravance Biopharma . “We are pleased with the comprehensive data package that was generated through our Phase 3 efficacy and safety studies and look forward to the FDA’s review of …

Robert Gottlander

OsteoReady LLC Announces New Management Structure | PR Newswire | 10/12/2017

… 2017 /PRNewswire/ – OsteoReady LLC, The Dental Implant Company for the General Practitioner ™ , announced a new management structure, effective today. Dr. Robert Gottlander , of New York, NY , has assumed the role of CEO of the Concord … with a basic surgical background and great access to the patient community. OsteoReady continues to develop its education platform, focus its training on efficient and safe techniques while developing products and solutions that are cost …

OsteoReady LLC Announces New Management Structure | CNBC | 10/12/2017

… CONCORD, Mass., OsteoReady LLC, The Dental Implant Company for the General Practitioner ™ , announced a new management structure, effective today. Dr. Robert Gottlander, of New York, NY, has assumed the role of CEO of the Concord … with a basic surgical background and great access to the patient community. OsteoReady continues to develop its education platform, focus its training on efficient and safe techniques while developing products and solutions that are cost …

David Li

OsteoReady LLC Announces New Management Structure | PR Newswire | 10/12/2017

… CEO of the Concord, MA based company. Dr. Marc Nevins , of Boston, MA , was appointed Chairman of OsteoReady LLC. Dr. David Little , of San Antonio, TX , will continue his role as Clinical Director while Mike … with a basic surgical background and great access to the patient community. OsteoReady continues to develop its education platform, focus its training on efficient and safe techniques while developing products and solutions that are cost …

OsteoReady LLC Announces New Management Structure | CNBC | 10/12/2017

… CEO of the Concord, MA based company. Dr. Marc Nevins, of Boston, MA, was appointed Chairman of OsteoReady LLC. Dr. David Little, of San Antonio, TX, will continue his role as Clinical Director while Mike … with a basic surgical background and great access to the patient community. OsteoReady continues to develop its education platform, focus its training on efficient and safe techniques while developing products and solutions that are cost …